Motor cortical inhibition and the dopaminergic system. Pharmacological changes in the silent period after transcranial brain stimulation in normal subjects, patients with Parkinson's disease and drug-induced parkinsonism.
about
Safety of transcranial magnetic stimulation in Parkinson's disease: a review of the literature.Interactions between two different inhibitory systems in the human motor cortexExcitatory and inhibitory corticospinal responses to transcranial magnetic stimulation in patients with minor to moderate head injuryA practical guide to diagnostic transcranial magnetic stimulation: report of an IFCN committee.Controlled study of 50-Hz repetitive transcranial magnetic stimulation for the treatment of Parkinson diseaseCortical silent period duration and its implications for surround inhibition of a hand muscleIntrahemispheric dysfunction in primary motor cortex without corpus callosum: a transcranial magnetic stimulation study.Pathophysiology of chorea and bradykinesia in Huntington's disease.The effect of exercise training in improving motor performance and corticomotor excitability in people with early Parkinson's disease.Slow (1 Hz) repetitive transcranial magnetic stimulation (rTMS) induces a sustained change in cortical excitability in patients with Parkinson's disease.The EEG correlates of the TMS-induced EMG silent period in humans.Magnetic stimulation of the central and peripheral nervous systems.Mechanisms of short-term training-induced reaching improvement in severely hemiparetic stroke patients: a TMS study.Flanker compatibility effects in patients with Parkinson's disease: impact of target onset delay and trial-by-trial stimulus variation.Cortical excitability and rest activity properties in patients with depressionEffects of antipsychotic medication on electromyographic responses to transcranial magnetic stimulation of the motor cortex in schizophrenia.Recurrent CSPs after Transcranial Magnetic Stimulation of Motor Cortex in Restless Legs Syndrome.Disrupted central inhibition after transcranial magnetic stimulation of motor cortex in schizophrenia with long-term antipsychotic treatment.Noninvasive brain stimulation for Parkinson's disease and dystonia.Decreased parvalbumin mRNA expression in dorsolateral prefrontal cortex in Parkinson's disease.Transcranial magnetic stimulation in disorders of consciousness.Cortical excitability and neurology: insights into the pathophysiologyTreatment and physiology in Parkinson's disease and dystonia: using transcranial magnetic stimulation to uncover the mechanisms of action.Pharmacological Manipulation of Cortical Inhibition in the Dorsolateral Prefrontal Cortex.Motor learning in animal models of Parkinson's disease: Aberrant synaptic plasticity in the motor cortex.Clinical neurophysiology and neurotransmitters.Transcranial magnetic stimulation follow-up study in early Parkinson's disease: A decline in compensation with disease progression?Local application of dopamine inhibits pyramidal tract neuron activity in the rodent motor cortex.Responses of single motor units in human masseter to transcranial magnetic stimulation of either hemisphere.Failure of activation of spinal motoneurones after muscle fatigue in healthy subjects studied by transcranial magnetic stimulation.Brain stimulation in Huntington's disease.Motor cortex plasticity in Parkinson's disease and levodopa-induced dyskinesias.Short interval intracortical inhibition and facilitation during the silent period in human.The dual nature of time preparation: neural activation and suppression revealed by transcranial magnetic stimulation of the motor cortex.Effects of fatigue on corticospinal excitability of the human knee extensors.Use of motor cortex stimulation to measure simultaneously the changes in dynamic muscle properties and voluntary activation in human muscles.Cortical excitability in patients with essential tremor.Clinical impairment of sequential finger movements in Parkinson's disease.Modulation of human motor cortex excitability by single doses of amantadine.Effects of dopaminergic treatment on functional cortico-cortical connectivity in Parkinson's disease.
P2860
Q26865819-7C063EAE-36FA-4213-9E8C-C452B51BE187Q28351658-ED4537D6-0CBD-406E-A662-2BF88D52BC79Q28363138-64460F2E-48F7-4C32-8FFE-2B100779BC15Q30382116-BF844C04-C37F-4285-BDEC-2843085C7162Q30430537-7A08107A-6B36-4AD5-8240-5C1264349165Q30448613-25DA5A6C-8BD3-421B-BF49-C526C9EEBD5DQ30477637-749DF38B-B1E0-446C-88D9-559018478636Q33647085-1556647F-A25A-43E6-BC2C-C855F789DBB6Q34340821-C5A6D7A5-D51D-41A3-B8A4-8DE5217C9548Q34383595-D4634DD7-7105-4192-AD78-8283527AE6A8Q34413673-F66B601A-8B87-48B0-A3F0-2FC4AD26F5A9Q34547625-5DBE6575-D9FB-4673-9986-7EFE1AFC8E73Q34993383-C1CB3D6A-5673-4C47-94CC-1415E83D7D09Q35792950-73C0EB2A-AED9-4E60-B8D6-08E59C1A8BB1Q35876039-B22049B4-5CB9-451E-9258-C8B7B65329AEQ36317248-A24AFC63-D38F-4143-AF7E-D683F7B41E35Q36425397-A14AB74A-DB3B-4BC0-A976-1D54CB6110F1Q36857163-D691180F-79F0-4736-8AC6-5F4C8A669F24Q37131286-B254BA31-A82C-4614-9E09-204F64B54589Q37276021-4841109B-C431-4D20-A51D-C9930BD3F857Q37693109-C8ECC947-3CAA-4B4B-A95A-0DCE1228571AQ38080951-8E188FC6-0C9F-4D84-AA86-4449C07795EEQ38207526-2000CB7D-0F32-4DC6-A3DC-22F870A42184Q38677830-66D04928-2CFF-43EC-BDFD-F9B2EA8CE1B7Q38739709-37232053-5AA3-4A0B-9931-E2F240C05066Q40430538-E39332A1-3915-4263-996A-59E435B80054Q41261915-03FE66C4-CAFA-4E18-B104-10FAC964CB16Q44238772-3DC62BE4-9306-4198-86FA-6074C577DE63Q44401235-DA4B39D1-0E1C-438F-B566-9124DA4A3001Q44489952-E68C5F8C-4EF7-4EF2-B17F-B522A592559BQ45295397-1AB102CE-480D-4E6C-B5AE-133FF1A9C12DQ46943000-C9ECAA70-73DA-4687-BDB1-CF2E72C53D25Q48094190-C11B3BE5-D835-4C8C-ADD9-7F71B6557C13Q48116547-A89F9052-86E8-4390-B849-25B5C4443F7FQ48259565-2F2021AA-10B4-462F-925A-144838EBD870Q48312495-819F28BD-9948-4B39-B344-1A2978FD41F1Q48396054-F32F9AF5-AB11-4DAC-B44C-CCAA5BBC79ECQ48456869-089FDD5A-418E-4858-87B6-DB05F4F67F1EQ48489411-1CE8ECA9-0840-45B3-8A91-5B3DB9FC1B0DQ48491350-7F461AB7-9A88-4AB8-BEE5-07F2C3A5B532
P2860
Motor cortical inhibition and the dopaminergic system. Pharmacological changes in the silent period after transcranial brain stimulation in normal subjects, patients with Parkinson's disease and drug-induced parkinsonism.
description
1994 nî lūn-bûn
@nan
1994年の論文
@ja
1994年学术文章
@wuu
1994年学术文章
@zh-cn
1994年学术文章
@zh-hans
1994年学术文章
@zh-my
1994年学术文章
@zh-sg
1994年學術文章
@yue
1994年學術文章
@zh
1994年學術文章
@zh-hant
name
Motor cortical inhibition and ...... and drug-induced parkinsonism.
@en
Motor cortical inhibition and ...... and drug-induced parkinsonism.
@nl
type
label
Motor cortical inhibition and ...... and drug-induced parkinsonism.
@en
Motor cortical inhibition and ...... and drug-induced parkinsonism.
@nl
prefLabel
Motor cortical inhibition and ...... and drug-induced parkinsonism.
@en
Motor cortical inhibition and ...... and drug-induced parkinsonism.
@nl
P2093
P921
P356
P1433
P1476
Motor cortical inhibition and ...... and drug-induced parkinsonism.
@en
P2093
P304
P356
10.1093/BRAIN/117.2.317
P407
P478
117 ( Pt 2)
P577
1994-04-01T00:00:00Z